1. Fenoldopam and renal hemodynamics in shiga toxin-related hemolytic uremic syndrome
- Author
-
Sara Testa, Cristiano Gandini, Antenore Giussani, Gianluigi Ardissino, Valentina Capone, and Giovanni Montini
- Subjects
Nephrology ,medicine.medical_specialty ,Thrombotic microangiopathy ,Fenoldopam ,030232 urology & nephrology ,030204 cardiovascular system & hematology ,urologic and male genital diseases ,Shiga Toxin ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Renal hemodynamics ,Child ,Escherichia coli Infections ,Shiga-Toxigenic Escherichia coli ,biology ,business.industry ,Hemodynamics ,Shiga toxin ,medicine.disease ,Systemic hemodynamics ,Hemolytic-Uremic Syndrome ,Pediatrics, Perinatology and Child Health ,Cardiology ,biology.protein ,business ,Off Treatment ,Vasodilating Agent ,medicine.drug - Abstract
Fenoldopam, a vasodilating agent, may represent a potential therapeutic opportunity to increase renal perfusion in those conditions where renal hemodynamics are severely impaired by vascular sub-occlusion, as, indeed, is the case in thrombotic microangiopathies. The renal resistance index (RRI) was measured, on and off fenoldopam, in 27 children with STEC-HUS. A 12% decrease in RRI was observed on fenoldopam compared to off treatment without changes in the systemic hemodynamics and with no side effects. If confirmed in larger series, fenoldopam may become an important addition to supportive care to reduce ischemic damage in STEC-HUS and improve long-term outcomes.
- Published
- 2021